Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 921 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Co-Existing with COVID-19: Should I go back to work? Do I... June 19, 2020 Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer January 18, 2022 FDA Approves Idecabtagene Vicleucel for Multiple Myeloma April 7, 2021 Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... April 26, 2022 Load more HOT NEWS Latest episode of our podcast for researchers President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... Research Says That Your Birth Order Can Shape Your Personality Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in...
